Q3 2022 Innate Pharma SA Earnings Call
[music].
Hello, and thank you for standing by my name is Regina and I will be your conference operator today at this time I would like to welcome everyone to the innate pharma publication of revenue for third quarter 2022 conference call. All lines have been placed on mute to prevent any background noise. After the speakers' remarks, there will be.
A question and answer session, if you'd like to ask a question. During this time simply press Star then the number one on your telephone keypad. If you would like to withdraw your question Press Star One again I would now like to turn the conference over to Henry Wheeler head of Investor Relations. Please go ahead.
Thank you good morning, good afternoon, and welcome everyone. This morning, <unk> issued a press release, providing a business update for our Q3 'twenty. Two results. We look forward to highlighting the progress made during the quarter as well as addressing future goals and milestones. The press release and today's presentation are both available on the last section of the website.
On slide two before we start I would like to remind you that we will make forward looking statements regarding our financial outlook. In addition to regulatory and product plan development.
These statements are subject to risks and uncertainties that may cause actual results to differ from those forecasted.
On slide three on today's call Youll see we will be joined by <unk>, Chief Executive Officer, who will then hand over to Jason <unk>, EVP and Chief Medical Officer.
And then Dennis morale EVP of business development and product portfolio strategy.
We will also have our CFO fredrik onboard on the line for Q&A.
I'll now hand, the call over to you.
Thank you Henry Good morning, Good afternoon, everyone and thank you for joining our call today. Please move to slide four and let me start by reminding you of our strategy.
Our strategy centers around three key priorities, where we look to drive value from our own R&D efforts to a later stage partnership well it makes sense to do so.
Firstly, we looked okay.
Driven by our lead proprietary product candidate liquid demand, which is in development for T cell lymphoma, we have readouts in <unk> happening in the second half of this year and two trials and the larger indication of T cell lymphoma underway.
Second we continue to shoot our pipeline and create longer term value by leveraging our antibody engineering capabilities to develop innovative molecules with a primary focus on our multi specific NK cell engagement proprietary platform called MK.
Sanofi has the most advanced and kick in the clinic and has selected another candidate and we are nearing the clinic with the others, notably with our 2020 targeted tetra specific NK it call. It <unk> 65 per watt.
Last but not least we are building a strong and sustainable foundation for our business.
Leveraging various partnerships across industry and academia here, our astrazeneca partnership with one of them is about which is continuing in lung cancer and our focus remains to leverage the value of our product as much as possible.
To ensure that if we can gain valuable competencies via a partner agreement, we will consider that in our development plans for the product.
This will further validate our sign and offer capital that we intend to invest to advance our early portfolio.
Yeah.
Before I hand over to Jonathan Please move to slide five.
Slide five is an overview of our pipeline.
Which shows how we continue to translate our science into a robust portfolio of proprietary and partnered assets.
It also illustrates how we are executing against our strategy with our lead proprietary asset like Ethernet supported by partner at an earlier stage product in particular from our NK cell engagement.
Platform.
We anticipate a number of potential clinical readouts and catalysts in the upcoming couple of years as our R&D engine looks to leverage our scientific knowhow to create a sustainable business.
I would like now to pass the call over to Jason who will review the progress made with our portfolio starting with <unk>, our most advanced proprietary asset Jason over to you.
Thank you man there on slide six let me start with our first in class humanized monoclonal antibody that targets the immune receptor Q3 deal too.
As you remember Q2 is an inhibitory receptor and approximately 65% of patients across all cutaneous T cell lymphoma.
And the telematic trial cohort, one recruiting sensory syndrome patients.
Could potentially be a pivotal cohort.
We announced that we will present preliminary data from this cohort at the Ash annual Commvault Congress in December .
From Iqos is ongoing as we have cohorts two and three where we are testing the hypothesis of non expresses an espresso is a Q3 deal to using the frozen companion diagnostic assay.
In September we presented preliminary data from the Mycosis <unk> cohort two at the <unk> Congress in Madrid.
Slide seven.
Summarizes the preliminary cohort two and three data in Mycosis <unk> presented at <unk> in September .
As a reminder, from the data presented last year as expected our scientific hypothesis confirmed in cohort two high global response rates in comparison to the benchmark and the non expressed in cohort and low global response rate and the non <unk> expressing cohort.
At the <unk> Congress this year at the presentation in the tier three tier two expressing cohort.
We were encouraged to see that in these late line patients with a median of four prior treatments.
<unk> demonstrated a 28, 6% or six responses.
We are particularly encouraged by the responses in the skin, where we saw a 57, 1% of our and 12 responses.
On slide eight we have the abstract published on the Ash Annual Congress 2022 website ahead of the Congress and publication of the data in December the abstract detailed that in this heavily pretreated post mogan, Lisa Mak patient pool with the median prior lines of therapy of six.
And $10 nine months of median follow up.
<unk> in the ITT population was 21, 6% with an IRR of 35, 1% in the skin and 37, 8% in the blood.
A favorable safety profile as mentioned.
We look forward to discussing the data in more detail after the presentation at the Ash annual Congress.
On slide nine let me summarize the progress we are making with <unk>.
We are pursuing a fast to market strategy for the kitimat and initial selling of surgery syndrome, whereas <unk> was granted granting us fast track designation and EU Prime designation in 2020.
We have expanded past centuries syndrome to mycosis <unk>.
We have seen encouraging preliminary data from our phase II trial in both cohorts.
For the century syndromes.
Proceeds from <unk> enrollment is on track with final data due in 2023.
Finally, we are continuing to enroll into peripheral T cell lymphoma, and the monetary P.
And combination trials in the relapse setting.
On slide 10, I would like to update you on a lithium ion to remind you <unk> is an anti <unk>, which acts upon the checkpoint pathway to purchase potentiate NK cell activation that we have licensed to astrazeneca for oncology.
On this slide you can see an overview of the late stage development plan for <unk> in lung cancer.
Just on the Astrazeneca sponsored phase II coast data Astrazeneca commenced Pacific nine.
Our phase III trial evaluating the combination of either modal as a mab or other killer map.
Dr value map in the Unresectable stage, III non small cell lung cancer setting.
Not progressed after concurrent chemo radiation therapy.
For the phase II <unk> study the three arms evaluated the combination of <unk> plus model as in App and devalue that molecular lab Astrazeneca <unk> 73.
As published in the journal of clinical oncology by Astrazeneca. After a median follow up of 11 five months.
The results are results of an interim analysis showed a hazard ratio of <unk>.
<unk> or <unk>, plus model is that versus to value Malone.
These results also showed an increase in the primary endpoint of confirmed or.
The value of our Paris, Mentalism, Mab overdue value, let alone a 36% versus 18% respectively.
We look forward to further updates from this study from Astrazeneca I will now hand over to <unk> to cover our <unk> platform.
Thank you Jason on Slide 11, I wanted to highlight our hopefully, Italy multi specific NK cell <unk> platform that we call and kit and get then meaningful antibody based NK cell engaging.
And get to divest of Daiichi <unk> technology made a value of the building blocks that is creating an entirely new cast of tightened our cost base. He can give you to a new synthetic immunity against cancer.
Operating platform, which is leveraging our scientific expertise and gives us space will be an engine followed by far our pipeline taking value multiple drug candidates addressing multiple gene targets the.
The backbone of the <unk> platform is based on the unique engagement of the activating NK cell receptor and <unk> 46, and 2016 on the NK cells, which allows for optimal auditing of the NK cell effector function.
Which can be further increased by addition of idea to volumes that can use their proliferation.
On slide 12.
Wanted to share with you why we are so excited for this platform and why there is a growing interest from the industry in the <unk> space.
As you can see on the left part of the slide on the beds can image published by the group of captive ethane at the MGM method of biennial work using adaptive and sale of encase eight.
The proof of concept that NK cells can induce a ton antitumor response, that's exactly what we are aiming to litigate with our molecules, which are designed to engage efficiently. The NK cells are the patients begin to cubo.
In the medium.
Can see the detail mckenney the motive action of the deposit if we can get money on.
On one hand, the engagement of the activating NK cell anti Tau and KC 46, and 2016 on NK cells.
And keep our EBIT ontogenetic dependent killing of the tumor as well as production of key cytokine for the anti tumor immune response.
On the other and the addition of <unk> to volumes, which targets. The IL two receptor again, a complex on NK cells induce NK cell proliferation within the tumor microenvironment, including increasing therefore, the number of antitumor I think does that.
This platform demonstrates compelling preclinical antitumor efficacy.
By the time, the PSC that you can see on the <unk> cost.
Lastly on the right you can see our growing pipeline of uncapped molecule.
We sell a fee, adding licensed two molecules, which I will cover it in the next slide.
Our most advanced <unk> and get the declared specific molecule targeting <unk> <unk> and <unk>.
65, or one four weeks, we plan to file an <unk> next year.
We also have other clinical targets.
We hope to provide some updates on <unk>.
On Slide 13, you can see our most advanced <unk> program is a <unk>, 1% to three targeted bispecific molecule called ICF 61, one off types.
579 that we have generated in collaboration with Sanofi.
License to them <unk> phase one trial.
We also announced over the summer that <unk> selected for further development of <unk> candidate.
<unk> 64, or one offs up by one four which is a <unk> targeted tie specific NK, what acute which is using <unk> sequencer data molecular format, which shows the efficacy of our platform.
We have announced 30 million euro in milestone to date from this partnership.
On slide 14, we are pleased to have with few presentation at ash highlighting the development for acute as well as several updates for the Rguest platform.
This includes a twofold, one with our partner Sanofi and an oral presentation on our CSO pocket there isn't.
We will present junket platform, including our latest debate. This last month in February both medicine.
We will have also update at the ESMO conference in December .
Anti CD 79 program called <unk>.
<unk> 201.
I will now turn to Monday for similarly of the catalyst ensco's.
Thank you Ian please move to slide 15.
As you can see we are working diligently to execute across all our strategic pillars, and we believe that we are laying the foundation to drive near and long term value.
Moving on to our clinical program, we expect to achieve a number of milestones over the next two years.
First as you heard from Jason our Phase III Telemark 34, a record and up continues to progress we have reported preliminary data this year.
The final data Q next year. In addition, our <unk> T cell lymphoma program initial data are expected next year for monolithic power. The lung cancer trials are underway and we continue to advance the adenosine pathway agents in the clinic, while we look forward to sharing our phase II plant in due course.
In parallel we continue to develop our anchor technology platform, including with our partner Sanofi and we are very encouraged by the preclinical results from our next generation NK cell engagement. We believe that this represents a natural evolution of our platform with data presented at comprehensive at the end of the year.
Finally, we look forward to further data on our proprietary anchored ebay 65 run as you've heard with the <unk> on track to be filmed filing next year.
Now, we'll move to the conclusion slide.
Lastly on slide 16, as you can tell we continue our exciting journey of tuning.
To build a business our business to create value for patients and stakeholders and in summary, we have positioned innate pharma for the future with our strategy and made meaningful progress throughout the year to date across all three strategic pillars. We have carefully managed our resources. So we can continue to invest in progressing our pipeline and then.
I'm very pleased that we continue to have a strong cash position with a runway into the second half of 2024 with $151 million as of September 32022, collectively we're driving value across our business and ultimately advancing our go to deliver innovative medicines to patients.
We look forward to keeping you updated on our progress.
That concludes our prepared remarks, we will now open the call to questions.
At this time I would like to remind everyone in order to ask a question simply press Star then the number one on your telephone keypad again that is star one our first question will come from the line of Yigal <unk> with Citigroup. Please go ahead.
Hi, Mandara and team. Thank you very much for taking the question I just had two one on selling that and then one on the tetra specific NK cell.
So I'm, telling that I was just interested in the cohort three which I know is the one with the non expresses you still had some good responses, albeit not all of them characterized.
<unk> I was just curious that because those patients are still expressing some low level of the target K R. <unk> or is there. Another reason and then on the on the Texas statistic and Cat. Obviously, CD 20 is a very well known target. So I'm assuming the idea there is to take some.
That's very well validated so that you can show what et cetera specific platform can do above and beyond the non target as opposed to introducing a totally new variable. In addition to this Texas specific can't get so if you could just elaborate on your thinking there. Thank you.
Thank you John for the two very important question and I'm sure. We'll start with the second one and I'm going to hand over to Jan has to set that set the context actually of the identification and selection of Destocking and then Jason will address your question about the level of activity we have seen.
With cohort three year Youre, absolutely correct, we it's not nailed it from zero, we have some activity and we have some.
Hypotheticals to explain actually that.
Level of activity, but let's start with the <unk> platform in <unk> 'twenty, one how are you getting any speaking.
Yes, I think youre height, we selected CD 20 in order to limit the number of valuable well with.
With this new <unk> molecule, we are progressing to the clinic.
New mechanism of action.
By relying on the activation when keep you focused in 16 as well as the cytokine in the same molecule. So as we're bringing these for the first time into the clinic, we decided to go after a very well validated target and <unk>. Obviously, one of these and which has also the advantage when you look at the expression.
It goes to other potential validated targets.
To be quite stable across the different lines of treatment, meaning that if you have like at least you Kim.
<unk> patients that are there.
<unk>, putting the targets, which basically from our perspective, the ideal candidate for this fill hopefully, Italy Hogan, indicating knowing that we are also <unk> at the preclinical stage with all the affiliates.
Thank you Annie.
And without without of course.
Adding too much as you have seen.
The data we have already presented.
Believe that we have really differentiated.
Asset based on at least on the safety profile.
<unk> generated so far but also on the preclinical antitumor activity that we have.
Published in various tumor models.
Masco dosing maybe two additional.
Additional question on <unk>.
Why we still have responses in cohort three despite the fact that Q2 level of expression is.
Below the 1% through short.
Yes, so just as a reminder, the cohort three is my couch it sounds <unk>.
In cohort two is you're expressing mycosis <unk>.
As you mentioned now.
There are different.
And there are different factors one is of course to heterogeneity of tumors number two is the assay shortly.
Uh huh.
Assets are conditions.
And because of those two we do see some low levels of activity even in the non expresses that were further exploring this also to both bank our assay more precise by looking at an all commerce cohort. So keep in mind that <unk> study does have an all commerce cohort also which will be looking at a.
And <unk> assay for keeping in mind that cohort two and cohort three.
Fresh frozen based assay. So these are sort of the reasons why we believe that you are seeing some low level activity.
Gotcha. Thank you.
Thank you.
Your next question will come from the line of David <unk> with SBB Securities. Please go ahead.
Hi, Thank you for your question for me on Telemark, but could I Mab and wonder.
If you can talk about what you think our regulatory expectations for accelerated approval.
And these diseases.
Focus on the global response rate or whether the skin or blood response rates.
Our years of net regulatory review and then the second question is as we've all been hearing a lot more about project Optimus I Wonder if you could remind us if you've done any randomized.
Optimization between three doses, that's likely to map and if not how you plan to continue that.
To meet.
Duluth project Optimus Oh My God.
Guidelines, but almost.
Almost guidelines from FDA. Thank you.
Thank you Dana.
Two very important question I think Jonathan is probably the right person to address first of all our our thinking about the accelerated approval of <unk> in <unk> syndrome and of course.
The evolution of the regulatory environment.
In the U S chosen.
Sure so.
In regards to the regulatory.
Sort of benchmark or what the regulatory regulators may be looking for we are in ongoing discussions with them. So at least at this point in time.
<unk>.
Want to say what they are considering for accelerated approval of course as we know this benchmark is this up for accelerated approval has become a bit tougher in the last few months or so.
Just because of the scrutiny that's been put on the accelerated approval program.
<unk>.
I think number two is in regards to project Optimus Interestingly.
Optimists as just dose justification and.
For us dose justification.
We have looked at us justification and continue to ensure that going forward.
A dose is correctly justify.
Alright, So I think we've been doing this for drug development for years on end.
I think <unk> it has been done.
Accordingly, I don't believe that the FDA has guided that you must do a randomized trial, but instead, they do say to explore several different doses at different levels and it's not necessarily based on randomization with statistical significance.
Okay.
Can you remind me.
Can you just remind us.
It happened.
Great.
How many characters you explored and sort of how many patients at various dose here.
Okay.
So we did explore.
Several different doses.
Explored both.
Hello.
Hello.
And I'll just kick it off.
I can still hear you well.
Okay. Okay, I don't know if I got cut off.
So we did explore several different doses, both intra patient dosing as well as.
Ah patients who received a single dose.
Throughout.
So we do have several different doses with.
Yes.
Adequate number of patients and doses.
At least that.
We were able to look at some of the PK and PD.
Okay.
Thank you.
Dana.
If you want we can follow up and maybe send you the.
The phase one data that was published as you know and and.
In new England.
A couple of years ago, where we have the details.
<unk>.
Okay.
And landscape.
Yes, sorry, I didn't I said okay.
Thank you.
Your next question will come from the line of Islam Pakula mechanic with H CW. Please go ahead.
Thank you this is RK from H C Wainwright.
Alright.
A couple of quick questions on the.
On the Telemark trial.
Yeah.
Now that you're going to present, some initial data on the surgery syndrome.
Dash.
But what's your expectation.
For the for the final results of this well.
Charles Charles.
Also for the same drug can you highlight.
Youre welcome.
Ill.
That would be helpful. Thank you.
Okay.
Hi, RK, let me thank.
Thank you good afternoon.
Thank you for the question, let me repeat them just to make sure we got them all right. So first one is about the data.
It can be presented at ash in particular with expectation, we have with regard to the.
Level of activity for <unk> in <unk>.
Syndrome, and other words and sort of targeted.
Targeted product profile and the second question is any update on the <unk> and then once again actually.
Jonathan is the right person to address both question Joseph back to you.
Joseph.
I didn't sorry, I didn't hear the PTC or question, but let me go ahead and address the <unk> question first.
Incendiary syndrome just.
The abstract that was published for us.
They'd have a globe just as a reminder, this was a very heavily pretreated population, who are personal and <unk> with a median number of six lines of therapy and with that we had seen in global confirmed overall.
Overall response rate of 21, 6%. So we were very encouraged are encouraged by that and we do expect that.
We continue to see encouraging data even in the final data set itself.
And I'm, sorry, what was the.
Question one.
One is so.
Just to maybe.
Make sure.
I got it right.
Okay, you are asking for.
Data on the <unk> and as you know.
We have two trials are in paper in T cell lymphoma, a company around phase one b trial.
Assessing the level of activity and the safety of <unk> in monotherapy and.
And we have.
Lisa sponsored priorities.
European Cooperative group.
Well known in heme that is testing the combination of academic.
With chemotherapy and in particular with the combination of <unk> and we we said that.
At the previous call that <unk>.
Interim.
The preliminary data will be presented in 2023, so next year.
Thank you thanks for taking my questions.
My question is on the line if not I will go to.
<unk> submitted questions.
No further phone questions at this time.
Okay.
So we have a question from Olga small lengths.
Brian Gagnon.
Three parts to the question Firstly could you give us any favorite what we should expect from the phase one data for <unk> <unk> and.
Do you see any read across for Ipi five tier one from the recent pools of anti CD 39 program by surface oncology.
I think it's.
It's fair to say that we will wait for the presentation at S module for further details.
We as you know we are starting.
Phase II trial in non small cell lung cancer and hope to be able to provide further details on this program very soon we are unable to comment on other companies and they are resource allocation and prioritization. So we'll stick to our program and the data that will be presented.
At the end of the year.
Thank you.
Question from Olga <unk>, 60, 501 fits into the highly competitive landscape of CD 20 targeting bi specifics.
Another important question I think.
<unk> I believe.
Ask a question along the same line we are fully.
We're of course competitive landscape here, but as he said.
Sure.
We will further.
If I read this landscape as we enter our IMT and defining the next year and we'll provide an update on the exact indication that we were pursuing but from what we have seen in the preclinical data. So far there is really an opportunity here to differentiate API 65, both on safety, but on improved efficacy.
<unk>.
I must also say that this.
Is that.
I guess, the first proprietary tailor specific and get the molecule to enter into the clinic in the.
The selection of a validated target was.
Way to mitigate the risk of going after a completely novel platform, which is which is that the trust specifics. So that's what is our approach to really mitigate the risk of the.
Novel platform by choosing.
<unk> distribution and validated target.
Thank you and last question from Olga should we expect the final data for liquids map Incisory syndrome to include similar highly pretreated patient population as per the interim update at ash.
Yeah, Hey.
Gary.
Uh huh.
<unk>.
And maybe stating the obvious but.
You you know that.
Patients in this trial is needed to have at least two lines.
Prior therapy and must be post model.
As you May remember as mortgage was still in the launching phase and some of the region. When we started the trial patients ended up being very late line and no reason to think that the rest of the trial would be any different. So we continue to enroll according to our inclusion exclusion criteria I E stage, four and stage four be a relapse refractory more.
With two or more prior lines of systemic therapy, including <unk> resolved. The main selection criteria and despite having a median of six lines of prior systemic therapy. We are encouraged by the top line asset safety efficacy and we look forward to discussing these data further at the Ash offers.
Dentation final data as I said earlier are due in 2020 for both our micros as Congress and <unk>.
Syndrome cohort.
And as a reminder.
As a reminder to ask a question on the phone simply press star one on your telephone keypad again that is star one.
Okay.
Sure.
We have a couple more questions submitted online.
Jimmy Chen at Evercore.
Similar question to before.
Do you plan to file for approval in SS first or wait two trials studying <unk> in NSS combined most of the main matrix considerations for decision.
Yes.
Back to Jason to recap our strategy.
In terms of development and registration for <unk> in <unk> MF.
Jason.
Thanks and under so.
I think.
Answer to your question do we plan to file for approval in SaaS first can wait to do trial studying <unk>.
Assets combined.
I think number one is this is going to depend a lot on the data. So we are keeping all our options open and that includes the potential to file for SaaS first that also includes the potential to power for both.
All during that time of course.
Considering even partners in the mix, so just kind of making sure all our options are open and what are the main matrix and considerations for this decision number one is the data itself will drive the decision. So the strength of the data will drive the decision number two is sort of the regulatory landscape as it starts to evolve.
We'll have a major influence on how we look at this and then third is just.
Our ability.
<unk>.
Have a look.
Look for a partner.
Okay.
Thank you Jason.
I have some further questions submitted online so Eric Bluebird Hugo and Stifel.
Question, one <unk> has delivered consecutively two highly confirming sets of data in MF and SaaS now many times in the past to explain the ability of <unk> to find a good partner will be heavily dependent on the interim data in PTC al. This is however, quite speculative at this stage and therefore, how should we think of both the value.
The future of the compound with PT sales does not deliver on promises.
Other words, how much dependent upon the <unk> is the future of <unk> overall.
Yes.
Thank you for a very important question.
I would say first of all.
Oh.
We follow the science and of course, we are.
We will define what is the right thing to do based on the data.
Well, we are of course, the business case in <unk> and also the potentially in MF and clearly.
Having a PCL indication would completely change the perspective of of these drugs moving from maybe.
Just a few hundred million to blockbuster, particularly is there I think at this point in time.
We will need to validate the signal through the <unk> trial and the preliminary data we.
We have so far and gaps tracked that is.
Submitted to ash.
Going into the high direction I think we'll wait for the particular data to emerge. It is the preliminary data next year to assess the various scenario, but keep in mind that we have two shots. If I may say of course, we have a monotherapy.
Trial, which is maybe a high risk, but nevertheless, I think an opportunity to identify.
Related activity in a heavily pretreated and difficult to treat patient population and we have also the combination trial with <unk>.
The Liza group, which of course in other way to explore the potential of <unk> in this disease and of course. These are beyond not only option that we are thinking of there are many other.
Opportunity in second line, but also in frontline that are being explored by the team, but I think it's important that we.
Generally the first set of data to better.
I understand actually how to position to date.
Value for these assets.
Okay.
Second question from Eric.
And kind of mark requiring patient required patients required to be treated pre treated with Morgan.
You've collected very advanced patients on average with six previous lines of treatments as time progresses is it fair to say that motor is now used earlier.
And therefore that you would treat less advanced patients if approved.
Again, I think it's an important question.
Similar to what I said earlier, it's <unk>.
Difficult to speculate on.
The.
Hey.
How heavily pre treated on the patient that will be recruiting in the.
In the in the next couple of months, but as I said.
Mobile was still in the launch phase and even even.
After launch we know that morga did not get reimbursed everywhere. So.
We had.
Clearly.
Some region wait a win win.
The drug was available and we ended up of course.
So we are recruiting patients with a very late line of therapy, and we didn't see a major.
Change in the.
I would say the access to more homeowners and mob in some part of the world at least in Europe . So there is no reason to think that the rest of the trial would be any different and we may end up with but yes, a heavily pre treated and.
Median of six line of therapy I think what is important is.
Hey.
Validate that.
We have an activity.
And the meaningful activity.
In patient who have been exposed to Montgomery is about I think.
Number one and number two.
This is an area of unmet medical need because our buy by design in the post <unk> setting.
And there is no established on the Ofcom of course the.
Data, we generate with Telemark would be of importance and of course, we will be discussing with the health authority when we have them.
Thank you last question from from Eric considering your previous comments was the ability of the CD 20 targets would it be fair to expect your drug to go first and a very advanced line of treatment once existing CD 20 antibodies have failed.
Okay.
Yes.
Yes. Thank you Eric for your question Yang in the late <unk>.
You mentioned.
'twenty target energen is pretty stable across the different lines of treatments, including monoclonal antibody that also.
Now T cell engages.
They're also in this type of NHL from jockeys, but they are they are targeting 2019, so I think thats, what youre seeing is a cookie.
Switching to SaaS option.
We can.
Start with advanced line of treatment.
We are mobilizing a very different mechanism of action.
Current approved treatments like monoclonal antibodies or car T. But also the one that are in the in the phase III in late stage development ideas seven gigawatts.
Thank you Denise I think we have no more questions online so like.
Maybe as a concluding remarks I'll remind you that as you have seen we continue to execute against our strategic priorities. We have a strong financial position. We are well funded into the second half of 2024 as we reported also results from our proprietary and partnered portfolio program.
These results set the stage for delivering both near and long term value. While also highlighting the strength and depth of our core R&D efforts and finally looking ahead, we will continue to administer academic program.
Move our early stage R&D activity in the clinic with our next generation <unk> platform.
While homeowners and Mark we look forward to further clinical development and early lung cancer with Charlie.
With Astrazeneca underway, which further in first of course, our strategy of building, a sustainable business and with a robust R&D engine.
Thank you very much wish you a wonderful day.
Okay.
Ladies.
And gentlemen that will conclude today's meeting we thank you all for joining you may now disconnect.
[music].